These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35661226)

  • 21. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Between-arm comparisons in randomized Phase II trials.
    Jung SH; George SL
    J Biopharm Stat; 2009; 19(3):456-68. PubMed ID: 19384688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial.
    Choodari-Oskooei B; Thwin SS; Blenkinsop A; Widmer M; Althabe F; Parmar MK
    Clin Trials; 2023 Feb; 20(1):71-80. PubMed ID: 36647713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
    Jaki T; Hampson LV
    Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.
    Arjas E; Gasbarra D
    BMC Med Res Methodol; 2022 Feb; 22(1):50. PubMed ID: 35184731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Admissible multiarm stepped-wedge cluster randomized trial designs.
    Grayling MJ; Mander AP; Wason JMS
    Stat Med; 2019 Mar; 38(7):1103-1119. PubMed ID: 30402914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Many-to-one comparisons after safety selection in multi-arm clinical trials.
    Hlavin G; Hampson LV; Koenig F
    PLoS One; 2017; 12(6):e0180131. PubMed ID: 28651023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size calculation for randomized selection trials with a time-to-event endpoint and a margin of practical equivalence.
    Dehbi HM; Embleton-Thirsk A; McCaw ZR
    Stat Med; 2022 Sep; 41(20):4022-4033. PubMed ID: 35688463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
    Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
    Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II trials: a long-term investment with promising returns.
    Sharma MR; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interval and point estimation in adaptive Phase II trials with binary endpoint.
    Nhacolo A; Brannath W
    Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian sample-size determination methods considering both worthwhileness and unpromisingness for exploratory two-arm randomized clinical trials with binary endpoints.
    Kakizume T; Zhang F; Kawasaki Y; Daimon T
    Pharm Stat; 2020 Jan; 19(1):71-83. PubMed ID: 31496045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
    Chu C; Liu S; Rong A
    Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
    Kunz CU; Kieser M
    Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase II clinical trials.
    Simon R; Wittes RE; Ellenberg SS
    Cancer Treat Rep; 1985 Dec; 69(12):1375-81. PubMed ID: 4075313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.